September 26, 2007 08:00 ET

Trinity Biotech Celebrates 15 Years on NASDAQ and Presents at William Blair & Company Small-Cap Growth Stock Conference, New York

DUBLIN, IRELAND--(Marketwire - September 26, 2007) - Trinity Biotech plc (NASDAQ: TRIB) (DUBLIN: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that Trinity Biotech is celebrating its 15th listing anniversary on NASDAQ this year. To celebrate and mark the occasion, Brendan Farrell, President, will host the closing ceremony in NASDAQ's New York Times Square offices at 4:00 p.m. Eastern Time, on Tuesday the 2nd of October.

While in New York, Brendan Farrell will also be speaking at the William Blair & Company Small-Cap Growth Stock Conference at 12:40 p.m. Eastern Time, on Wednesday the 3rd of October. This event will be web cast and can be accessed on http://www.wsw.com/webcast/blair9/trib/

Trinity Biotech develops, acquires manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners.

Trinity Biotech trades its Ordinary Shares on the Irish Stock Exchange and ADR's on Nasdaq. Each ADR represents four Ordinary Shares. For further information please see the company's website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.